One company this is starting to capture the attention of investors is Biomoda Inc. Located in Albuquerque, New Mexico, Biomoda has established a stellar reputation as a cancer diagnostics company that is focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. Today, Biomoda took a step towards enhancing their future with the announcement it has been granted a patent in Mexico.
The Mexican patent was issued for Biomoda’s proprietary prophyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light. This patent is similar to foreign patents that are now effective in Japan, Australia and ones that are pending in Europe and Canada.
One of the leaders at Biomoda is John Cousins who serves as the company President. When asked what this patent means to the future of the young company, Cousins was quoted as saying, “This patent represents another step in protecting our intellectual property rights internationally.” Cousins further added, “We are strategically building our IP portfolio with an eye on the eventual commercialization and marketing of our CyPath(NYSE:R) diagnostic assay to address the global issue of lung cancer mortality.”
Currently, Biomoda is trading in the $0.18 range. With this new Mexican patent and many other happenings in the company pipeline, Biomoda is a company that is quickly establishing a global presence. To learn more about Biomoda, visit the company website at: biomoda.com.
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Disclosure: no positions